secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapForce Inc. (CFOR)
CIK:        0001293818
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001079973-23-000728
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OpGen Q1 revenue $0.91M (up 94% YoY), FDA UTI submission, Fisher deal, cash burn guidance
--------------------------------------------------------------------------------

- Q1 2023 revenue $0.91M, up 94% YoY ($0.47M) and 26% QoQ ($0.72M).
- Submitted De Novo FDA application for Unyvero UTI panel; FDA confirmed complete review initiated.
- Non-exclusive distribution agreement with Fisher Healthcare for Unyvero A50 platform and tests.
- Cash $7.0M at Mar 31; 2023 guidance: revenue $4-5M, net cash consumption $4.5-5M/quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293818/000107997323000728/0001079973-23-000728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293818/000107997323000728/opgen_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-23-000728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer